Репозиторий Университета

© 2019 Elsevier Ltd Schizophrenia is a severely debilitating, lifelong psychiatric disorder affecting approximately 1% of global population. The pathobiology of schizophrenia remains poorly understood, necessitating further translational research in this field. Experimental (animal) models are becoming indispensable for studying schizophrenia-related phenotypes and pro/antipsychotic drugs. Mounting evidence suggests the zebrafish (Danio rerio) as a useful tool to model various phenotypes relevant to schizophrenia. In addition to their complex robust behaviors, zebrafish possess high genetic and physiological homology to humans, and are also sensitive to drugs known to reduce or promote schizophrenia clinically. Here, we summarize findings on zebrafish application to modeling schizophrenia, as well as discuss recent progress and remaining challenges in this field. We also emphasize the need in further development and wider use of zebrafish models for schizophrenia to better understand its pathogenesis and enhance the search for new effective antipsychotics.

© 2018, Media Sphera Publishing Group. All rights reserved. A number of frequently discussed issues of clinical psychiatry include comparing the advantages and disadvantages of typical and atypical antipsychotics. It is believed that atypical antipsychotics are less likely to cause extrapyramidal disorders and have a more significant effect on the negative symptoms of schizophrenia compared to typical drugs. However, many randomized controlled and cohort studies, as well as systematic reviews and meta-analyses carried out on their basis, allow questioning the superiority of second-generation antipsychotics over their predecessors, in particular in terms of tolerability. Current scientific evidence provides sufficient evidence for the clinical use of chlorpromazine and other traditional antipsychotics, along with more recent medicines.